Blended Learning Journey Cardiovascular Disease and Hypertension 2024

from 30 April to 8 November 2024


Beta-blockers are recommended by the most recent European guidelines (McDonagh et al. 2021, Knuuti et al. 2020) as first-line therapy for coronary artery disease and heart failure with reduced ejection fraction. However, physicians underuse these drugs in patients who present with co-existing comorbidities but who are not contraindicated, which can negatively affect patient outcomes and long-term prognoses (Paolillo et al. 2021). The increasing prevalence of heart failure, with its high morbidity and mortality rate, has highlighted the need for more education about accurate differential diagnosis and management. Arterial hypertension and hypercholesterolemia increase the likelihood of cardiovascular disease, but early detection of these conditions is low due to inadequate screening, insufficient assessment, poor management, and poor treatment adherence (Tadic and Cuspidi 2019, Mach et al. 2020). Education and support of both healthcare professionals and patients, particularly women transitioning to menopause, is important in understanding risk-reducing strategies, healthy behaviours and treatment adherence. Ever-increasing pressures on healthcare professionals may only be met with innovations, including embracing both telemedicine and telemonitoring, both of which have shown promise for hypertension management (Omboni et al. 2020).

Learning Objectives

At the end of the blended learning journey, participants should be able to:

Target Audience

Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who manage patients with hypertension and heart failure. Some content of interest to gynaecologists, midwives, nurses involved in women’s health care.


The official language of this educational programme will be English. Simultaneous translation into Russian and Chinese will be provided.

Continuing Medical Education

The BLENDED LEARNING JOURNEY ON CARDIOVASCULAR DISEASE AND HYPERTENSION 2024 will be submitted for CME accreditation from the European Accreditation Council for Continuing Medical Education (EACCME), the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) and for Continuing Professional Development (CPD) credits.

Blended Learning Journey on Cardiovascular disease and hypertension 2024

from 30 April to 8 November 2024

E-learning Activities

E-learning Activities

This learning journey is a structured educational programme comprising:

Video Presentation

LAUNCH 30 April 2024

Combination of hypertension and hypercholesterolemia

Podcast & Infographic

LAUNCH 28 June 2024

Best practices for diagnosis and management of patients with HFpEF

Podcast & Infographic

LAUNCH 30 September 2024

The ongoing role of beta blockers in the CVD treatment paradigm

CME Live Webinar

LAUNCH 8 November 2024

Women’s health, CVD and hypertension

Final Programme<

Download STD & Scientific Programme

Save the Date
Programme soon